A global network of practitioners

RGCC operates in over 20 countries

With bases in five continents

Our laboratories worldwide

Equipped with world-leading technology and staffed by experts in their fields

• RGCC Switzerland
• RGCC Greece
• RGCC Central Europe
• RGCC India

Why RGCC?

RGCC’s CTC Tests are Unique & Empowering

• 3 main CTC panels - Oncocount, Oncotrace, Oncotrail
• CTCs + phenotype markers + stemness markers
• Empowering - Armed with the information you need to know about how to properly manage your patient’s care

Positive vs. Negative Selection

• Most labs - positive selection: look for specific target to the exception of all other cancer cell populations
• Monitoring with positive selection is not accurate and can be misleading
• RGCC - negative selection: identifies all cancer cells

Partnership

• Most labs offer a single test
• RGCC partners with you throughout the patient’s entire cancer journey
• Baseline + Treatment Options + Monitoring + Therapies

Personalization

• Current treatment model = One-size-fits-all
• RGCC model = individualization >>> Personalized protocols
• Onconomics Plus - The most comprehensive panel available
  • Genetic and Physiological Expressions
    • More than 50 Chemotherapeutic Agents
    • More than 45 Natural Substances

Our testing solutions

Advanced testing options to empower you to make informed decisions about your cancer care.

• RGCC screening test
  • Onco-D-clare
• RGCC baseline and follow-up tests
  • Oncotrace
  • Oncotrail
  • Oncocount
• RGCC treatment protocol tests
  • Onconomics Plus
  • Onconomics
  • Onconomics Extracts+
  • Onconomics Extracts
  • Immune Frame (for cellular therapies)
• RGCC advanced diagnostic tests
  • aCGH
  • ChemoSNiP
  • Metastat
  • CAMBISeq®
  • InVyomma Plus
• PrimeSpot genetic test
• PaldiSpot genetic test

Onco-D-clare

• Onco-D-clare is a cancer screening test based on the interaction of molecular
  biology with machine learning algorithms. This screening test can help detect
  cancer before symptoms appear.
• Peripheral blood mononuclear cells are isolated from blood samples, and gene
  expression analysis is performed in more than 90 genes. Their expression
  profile is then used for the classification of the sample as healthy or unhealthy.
• The Onco-D-clare test provides individuals with essential information to help
  them make better-informed decisions about future health and well-being.
• The test is clinically validated and highly accurate (≈93%).

Onco-D-clare sample report

Oncotrace

• Used as a BASELINE and FOLLOW-UP tool to determine starting point, and monitoring effectiveness of treatment protocols
• May also be used for long-term monitoring following successful treatment for early detection of recurrence
• Detects presence of ALL cancer types (except those of CNS origin)
• Detects the presences and number of CTCs in the blood (circulating tumor cells)
• Detects phenotype markers which are associated with tissue origin
• Detects Stemness Markers to monitor activity level of the CTCs to determine prognosis (potential for the cancer to proliferate (be aggressive), metastasize, resist treatment, or recur) and to determine when care is done
• For hematologic (blood) & solid
• Sample Type: Blood

Oncotrail

• Use when you know the primary origin of the tumor for specific cancer types only (see list below)
• Used as a BASELINE and FOLLOW-UP tool to determine starting point, and monitoring effectiveness of treatment protocols.
• More suitable as a FOLLOW-UP tool following the Oncotrace once it is determined no secondary cancer is present
• Contains more biomarkers than Oncotrace for the specific type of cancer
  • Breast
  • Colon
  • GI
  • Lung
  • Melanoma
  • Prostate
  • Sarcoma
• May also be used for long-term monitoring following successful treatment for early detection of recurrence
• Detects the presences and number of CTCs in the blood (circulating tumor cells)
• Detects phenotype markers which are associated with specific tissue origin.
• Detects Stemness Markers to monitor activity level of the CTCs to determine prognosis (potential for the cancer to proliferate (be aggressive), metastasize, resist treatment, or recur) and to determine when care is done
• For hematologic (blood) & solid tumors
• Sample Type: Blood

Oncocount

• Used as a FOLLOW-UP tool for monitoring effectiveness of treatment protocols
• Can be used as a BASELINE tool as well, when interested only in CTCs
  enumeration.
• Detects presence of ALL cancer types (except those of CNS origin)
• Detects the presence and number of CTCs in the blood (circulating tumor cells)
• For hematologic (blood) & solid tumors
• Sample Type: Blood

Onconomics Plus

• Most comprehensive individualized profile available (preferred for all baseline testing)
• Combination of Onconomics and Onconomics Extracts Panels
• Includes chemosensitivity testing of both chemotherapeutic agents AND natural substances
• Answers the question: “Which are the most effective chemotherapeutic agents and natural substances?”
• Detects the presence and number of CTCs (does not contain phenotype or stemness markers as does Oncotrace and Oncotrail)
• Analyzes validated tumor-related Gene expressions used for customization of treatment protocols
•  Includes Resistance Factors to further refine timing and rotation of treatment protocols
• Includes Chemosensitivity (Pharmacodynamic) testing to determine the effectiveness of >50 Chemotherapeutic agents + 60 targeted drugs + >50 natural substances + 5 additional substances upon request at no additional cost
• For hematologic (blood) & solid tumors
• Sample Type: Blood

What all is tested with Onconomics Plus?

The beauty of this test is the ability to test what the cancer in a patient’s body responds to without having any idea of where the primary tumor is located.

The lab will test more than 50 common chemotherapy drugs and more than 45 natural substances for all types of cancers, while most other labs are often limited to the approved drug list and do not offer natural substance testing at all. The natural substances we test cover cytotoxic agents; immunostimulants/immunomodulators, and PK Inhibitors. The results show the % of sensitivity and/or resistance of each individual agent to induce apoptosis (cell death) to that patient’s cancer cells, i.e. ex-vivo.

Onconomics Plus also includes 53 chemotherapeutic agents, including:

• Alkylating agents
• Epothilone
• Inhibitors topoisomerase I
• Inhibitors topoisomerase II
• Nucleus spindle stabilizers
• Nucleoside analogues
• Resistant Factor MDR1
• Resistant Factor MRP
• Resistant Factor LRP
• Resistant Factor GST

The results show in percentages the sensitivity and resistance of each agent tested. In other words, which chemotherapy works best against the cancer cells in that person’s body.

You also receive results on 70+ tumor-related genes (these are very important):

• Related to growth factors and proliferation stimuli
• Related to self-repair and resistance
• Related to for angiogenesis
• Related to cell cycle regulation and immortalization/apoptosis
• Related to angiogenesis-metastasis
• Related to drug metabolism

You receive these results in percentages of overexpression or down regulation. This will give you detailed information about the cancer and its ability to grow and metastasize faster, its ability to resist certain drugs, and its tendency to become immortal and much more.

Onconomics

• Comprehensive, individualized profile
• Answers the question: “Which are the most effective chemotherapeutic agents?”
• Detects the presence and number of CTCs (does not contain phenotype or stemness markers as does Oncotrace and Oncotrail)
• Analyzes validated tumor-related Gene expressions used for customization of treatment protocols
• Includes Resistance Factors to further refine timing and rotation of treatment protocols
• Includes Chemosensitivity (Pharmacodynamic) testing to determine the effectiveness of >50 Chemotherapeutic agents + 60 targeted drugs + 5 additional substances upon request at no additional cost
• For hematologic (blood) & solid tumors
• Sample Type: Blood

Onconomics Extracts+

• Comprehensive, individualized profile
• Answers the question: “Which are the most effective natural substances?”
• Detects the presence and number of CTCs (does not contain phenotype or stemness markers as does Oncotrace and Oncotrail)
• Analyzes validated tumor-related Gene expressions used for customization of treatment protocols
• Includes Resistance Factors to further refine timing and rotation of treatment protocols
• Includes sensitivity (Pharmacodynamic) testing to determine the effectiveness of >50 natural substances + 5 additional substances upon request at no additional cost
• Anti-Cancer effect measured by studying:
  • Inhibition of - Signaling Transduction Pathways, Growth Factor Receptors, and Angiogenesis Receptors
  • Immunostimulation/Immunomodulation - Release of Cytokines and increase of PBMC & NK cells
  • Cytotoxic Effect – Activation of Caspase and Cytochrome C
• For hematologic (blood) & solid tumors
• Sample Type: Blood

Onconomics Extracts

• Individualized profile showing the efficacy of treatment using natural substances
• Answers the question: “Which are the most effective natural substances?”
• Detects the presence and number of CTCs (does not contain phenotype or stemness markers as does Oncotrace and Oncotrail)
• Includes testing of >50 natural substances + 5 additional substances upon request at no additional cost
• Anti-Cancer effect measured by studying:
  • Inhibition of - Signaling Transduction Pathways, Growth Factor Receptors, and Angiogenesis Receptors
  • Immunostimulation/Immunomodulation - Release of Cytokines and increase of PBMC & NK cells
  • Cytotoxic Effect – Activation of Caspase and Cytochrome C
• For hematologic (blood) & solid tumors
• Sample Type: Blood

Immune Frame (for cellular therapies)

• When you need to evaluate the immune status of the patient to determine eligibility for use of Cellular Therapies. It is also used for establishing a baseline and monitoring therapeutic response.
• Prerequisite for RGCC Cellular Therapies
• Important for treatment algorithm to determine eligibility for RGCC Cellular Therapies
• Determination of:
  • Cachexia (a.k.a. Wasting Syndrome) - A general state of ill health involving marked weight loss and muscle loss
  • Presence and stimulation of DC’s (dendritic cells)
  • Specific Humoral and Cellular Immunity
  • Non-specific Cellular Immunity
  • Immunosuppressive Mechanisms
  • Activation of T and B Memory cells for long-term immunity

aCGH

• Use when you don’t know the primary origin of the tumor
• Detects chromosomal abnormalities that may be associated with the primary tumor
• For hematologic (blood) & solid tumors
• Sample Type: Blood

ChemoSNiP

• Pharmacokinetics (how body metabolizes drugs)
• Examines inherited variations in genes that dictate drug response and explores the way these variations can be used to predict whether a patient will have a good response to a drug, a bad response, or no response at all.
• When used together with data from chemosensitivity testing, it helps to narrow the selection to the most effective and least toxic therapeutic agent.
• Sample Type: Blood or Swab

Metastat

• Advanced test to detect blood born markers that can accurately determine whether a secondary tumor is likely to develop and its likely location
• Potential Sites of Metastasis:
  • General
  • Lung
  • Brain
  • Skin
  • Pleura
  • Liver
  • Bones

CAMBISeq

• Cancer Analysis Mutational Burden Instability Sequencing
• Technique: NGS (Next Generation Sequencing)
• Identifies beneficial mutations for cancer treatment (FDA approved treatments and in clinical trials)
• The higher the number of mutations, the better the outcome for the patient when Immune Checkpoint Inhibitors (ICIs) are used
• Analyze mutational profile of CTCs
• DNA & RNA is studies to detect splice variants and fusions
• High Coverage = means the test is able to detect very rare mutations
• Typically used in medical oncology after first-line therapies have been exhausted to determine if there are any immunotherapy, targeted therapies, or clinical trials available as additional treatment options
• Predicts efficacy of immunotherapy or targeted therapy

PrimeSpot

• The PrimeSpot test detects and quantifies specific virus and Lyme disease-associated species in a patient’s sample
• Virus sample report available here
• Autoimmune sample report available here

PaldiSpot

• The PaldiSpot test detects the present of Borrelia, Babesia, and Bartonella genospecies in a patient’s sample
• Sample report available here

Our therapy solutions

Our team of multi-disciplinary scientists combines groundbreaking research with best-in-class technology to develop targeted therapies to improve patient outcomes.

SOT Therapy

Supportive Oligonucleotide Therapy (SOT) is a personalized therapy for cancer, viruses and pathogens including Lyme Disease. The SOT has the ability to bind to a specific gene of interest that controls the cancer cell or pathogen by disrupting the critical process that promotes its survival or growth. During this therapy, we analyze a patient’s blood and we create a complementary oligonucleotide sequence that is designed to interrupt survival or growth of the cells.

Vaccine Prep (ATA)

Vaccine Prep (ATA) is a new type of immunotherapy that activates or strengthens specific immune cells. The body's own cells are specifically designed to recognize and destroy cancer cells. We use the cellular fragments of dying tumor cells (CTCs). These include organelles, mitochondria, cell membranes and cellular RNA and DNA. In our laboratory, we stimulate the development of dendritic cells and thus promote tumor antigen therapy.

Dendritic Cell Therapy

The aim of dendritic cell therapy is to activate or strengthen the immune system. In immunotherapy, specific immune cells are used to target cancer cells. The therapy method uses so-called dendritic cells, which can recognize specific antigens on the surface of cancer cells. Thanks to improved tumor defense and a reduction in systemic side effects, the therapy is considered a promising treatment approach.

VAXO-Q-RE

Vaxo-Q-Re is a new advanced therapy consisting of five types of immune cells; macrophages, NK cells, dendritic cells, cytotoxic T lymphocytes and antibody producing plasma cells. Tested on breast cancer cells but effective at treating all forms of the disease, the adoptive T cell-based therapy encourages the body’s immune system to target cancer cells. Vaxo-Q-Re has been in development by RGCC scientists for more than five years and is now categorized as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency (EMA).

Testimonials